Potential drug target for cardiomyopathy identified
A team from the Stanford University School of Medicine (CA, USA) have reported that a surge in the platelet-derived growth factor pathway could be the cause of abnormal cardiac rhythms experienced by patients with cardiomyopathy. They also believe that this could be treated with existing drugs.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>